184 related articles for article (PubMed ID: 28077534)
1. Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding.
Payen JF; Berthet M; Genty C; Declety P; Garrigue-Huet D; Morel N; Bouzat P; Riou B; Bosson JL;
Br J Anaesth; 2016 Oct; 117(4):470-476. PubMed ID: 28077534
[TBL] [Abstract][Full Text] [Related]
2. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
[TBL] [Abstract][Full Text] [Related]
3. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
Spinella PC; Perkins JG; McLaughlin DF; Niles SE; Grathwohl KW; Beekley AC; Salinas J; Mehta S; Wade CE; Holcomb JB
J Trauma; 2008 Feb; 64(2):286-93; discussion 293-4. PubMed ID: 18301188
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated coagulation factor VII and bleeding trauma patients.
Rizoli SB; Nascimento B; Osman F; Netto FS; Kiss A; Callum J; Brenneman FD; Tremblay L; Tien HC
J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
[TBL] [Abstract][Full Text] [Related]
5. Prolonged prothrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes.
McMullin NR; Wade CE; Holcomb JB; Nielsen TG; Rossaint R; Riou B; Rizoli SB; Kluger Y; Choong PI; Warren B; Tortella BJ; Boffard KD;
J Trauma; 2010 Jul; 69(1):60-9. PubMed ID: 20622579
[TBL] [Abstract][Full Text] [Related]
6. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage.
Boffard KD; Choong PI; Kluger Y; Riou B; Rizoli SB; Rossaint R; Warren B;
Transfusion; 2009 Dec; 49 Suppl 5():240S-7S. PubMed ID: 19954486
[TBL] [Abstract][Full Text] [Related]
7. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
Selin S; Tejani A
Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
[TBL] [Abstract][Full Text] [Related]
8. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly.
Duchesne JC; Mathew KA; Marr AB; Pinsky MR; Barbeau JM; McSwain NE
Am Surg; 2008 Dec; 74(12):1159-65. PubMed ID: 19097529
[TBL] [Abstract][Full Text] [Related]
9. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.
Hauser CJ; Boffard K; Dutton R; Bernard GR; Croce MA; Holcomb JB; Leppaniemi A; Parr M; Vincent JL; Tortella BJ; Dimsits J; Bouillon B;
J Trauma; 2010 Sep; 69(3):489-500. PubMed ID: 20838118
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
Palmason R; Vidarsson B; Sigvaldason K; Ingimarsson JP; Gudbjartsson T; Sigurdsson GH; Onundarson PT
Acta Anaesthesiol Scand; 2012 May; 56(5):636-44. PubMed ID: 22489992
[TBL] [Abstract][Full Text] [Related]
11. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.
Rizoli SB; Boffard KD; Riou B; Warren B; Iau P; Kluger Y; Rossaint R; Tillinger M;
Crit Care; 2006; 10(6):R178. PubMed ID: 17184516
[TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
13. [Activated recombinant factor VII (Novoseven) in multiple trauma patients: an outcome analysis].
Grinţescu I; Tulbure D; Mirea L
Chirurgia (Bucur); 2006; 101(6):615-24. PubMed ID: 17283837
[TBL] [Abstract][Full Text] [Related]
14. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
15. The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering from blunt force trauma compared with penetrating trauma: a systematic review.
Devlin R; Bonanno L; Badeaux J
JBI Database System Rev Implement Rep; 2016 Mar; 14(3):116-38. PubMed ID: 27532142
[TBL] [Abstract][Full Text] [Related]
16. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
[TBL] [Abstract][Full Text] [Related]
17. Use of recombinant factor VIIa in US military casualties for a five-year period.
Wade CE; Eastridge BJ; Jones JA; West SA; Spinella PC; Perkins JG; Dubick MA; Blackbourne LH; Holcomb JB
J Trauma; 2010 Aug; 69(2):353-9. PubMed ID: 20699744
[TBL] [Abstract][Full Text] [Related]
18. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.
Perkins JG; Schreiber MA; Wade CE; Holcomb JB
J Trauma; 2007 May; 62(5):1095-9; discussion 1099-101. PubMed ID: 17495707
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with recombinant activated factor VII in a series of 45 trauma patients.
Felfernig M;
J R Army Med Corps; 2007 Mar; 153(1):32-9. PubMed ID: 17575875
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients.
Nascimento B; Lin Y; Callum J; Reis M; Pinto R; Rizoli S
Clinics (Sao Paulo); 2011; 66(1):101-6. PubMed ID: 21437444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
